Candidate to Clinic: a webinar and live Q&A Session
On 4th December, Bionow hosted a webinar titled ‘Candidate to Clinic’ where members of Seda PDS and ApconiX presented their recent DMPK and pharmaceutics experiences of Project Optimus, followed by a live Q&A Session.
Understanding the ADME (Absorption, Distribution, Metabolism, and Excretion) of drug candidates is crucial for successful drug discovery and development, particularly in oncology. As a drug candidate progresses towards clinical trials, comprehending its pharmaceutical properties becomes essential to ensure the formulation is efficient, safe and cost-effective.
In alignment with FDA’s Project Optimus which aims to reform dose optimisation and selection in oncology drug development, Seda PDS and ApconiX shared insights from their collaborative experiences in DMPK, toxicology and pharmaceutics. They provided valuable observations on how these disciplines address challenges, facilitate the design and discovery of new therapies and support both preclinical and clinical stages of drug development.
The Candidate to Clinic webinar concluded with the team answering questions and discussing how their expertise can support other projects, with an opportunity for the audience to gain deeper understanding and explore innovative solutions in drug development.
Speakers:
Ken Page, DMPK Specialist at ApconiX
Linette Ruston, Chief Scientific Officer at Seda PDS
Jake Dickinson, Principal Modeller at Seda PDS
Chris Piekarski, Principal Scientist: DMPK at Seda PDS